Details of the Drug Combinations

General Information of This Drug (ID: DMWO5ZR)

Drug Name

Cediranib DMWO5ZR

Synonyms

Recentin; AZD 2171; AZD2171; M6294; AZD-2171; ZD-2171; AZD2171, Recentin, Cediranib; Cediranib (USAN/INN); 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

Indication

Disease Entry	ICD 11	Status	REF
Peritoneal cavity cancer	2C51.Z	Phase 3	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cediranib + Panobinostat	DCKHT09	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

7 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Lomustine + Cediranib	DCUBRSD	Lomustine	Recurrent Glioblastoma	[3]
Olaparib + Cediranib	DCDK8WS	Olaparib	Ovarian Cancer	[4]
Oxaliplatin + Cediranib	DCIEZJJ	Oxaliplatin	Metastatic Colorectal Cancer	[5]
Saracatinib + Cediranib	DC5AF9T	Saracatinib	Neoplasms	[6]
Sunitinib + Cediranib	DCKLCII	Sunitinib	Sarcoma, Alveolar Soft Part	[7]
Temsirolimus + Cediranib	DCUWF06	Temsirolimus	Endometrial Cancer	[8]
Olaparib + Cediranib	DCBU3LB	Olaparib	Ovarian Cancer	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5664).
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	ClinicalTrials.gov (NCT00503204) Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
4	ClinicalTrials.gov (NCT02681237) A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer
5	ClinicalTrials.gov (NCT00494221) A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
6	ClinicalTrials.gov (NCT00475956) Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
7	ClinicalTrials.gov (NCT01391962) Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
8	ClinicalTrials.gov (NCT01065662) AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
9	ClinicalTrials.gov (NCT02340611) A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib